ANNUAL REPORT 2016-2017 · 8 \ CROSS-SECTOR BIOTECH / 9 ANNUAL REPORT 2016-2017 The 2016 European Biotech Week, organised between 26 September and 2 October, broke new records building

$Page 1: ANNUAL REPORT 2016-2017 · 8 \ CROSS-SECTOR BIOTECH / 9 ANNUAL REPORT 2016-2017 The 2016 European Biotech Week, organised between 26 September and 2 October, broke new records building$
ANNUAL REPORT2016-2017

STRENGTHENING BIOTECHNOLOGY AND THE EU PROJECT

The European biotechnology industry, as a key contributor to growth, jobs and innovation in all 28 EU countries, remains fully supportive of the European Project and of a strong, united and open Europe.

The Brexit vote which occurred a year ago ushered in a period of political turbulence and uncertainty which will wield a substantial impact not only on the future of European integration but also on the international community as a whole, which is why the entire world is paying close attention to the ongoing negotiations. This testifies to the expectation that the United Kingdom and the European Union (EU) will continue to lead the world in enlarging and promoting a free and open market economy. Moreover, in the international community today, where the global order is beset with challenges, the presence of a strong, united Europe is essential.

In fact, biotechnology has been a pillar of EU competitiveness and innovation for the past twenty years. Our three sectors, spanning healthcare, industrial and agricultural biotechnology, have heavily invested in the European project with a presence of over three thousand companies in Europe today, ranging from start-ups of less than ten people to multinational companies present in multiple EU countries.

This investment underpins our support for a strong, competitive Europe delivering solutions that benefit patients, farmers, other end users and citizens as a whole. At the same time, the need to boost economic recovery, access fresh investment, create new markets and cultivate a highly skilled workforce is becoming increasingly critical, if the EU is to overcome the current political turbulence and even thrive.

Bold political leadership which recognises and plays to Europe’s competitive and technological strengths rather than stifling them, is needed now more than ever, if the EU is to create a stronger, smarter Europe delivering the benefits, jobs and growth that its citizens need. Based on the work outlined in this report, EuropaBio with all its members stand ready and eager to support this ambition.

Carlo Incerti, MD

EuropaBio Chairman

TABLE OFCONTENTS

Cross-sectorbiotech

Healthcarebiotech

Agricultural biotech

Industrialbiotech

Our team Our members

7 15 21 27 32 34

CROSS-SECTORBIOTECH

In addition to priorities in the healthcare, industrial and agricultural

biotech sectors, EuropaBio works on a number of initiatives to strengthen

biotechnology in Europe. These include supporting and raising awareness

of biotech SMEs, global industry collaboration through the International

Council of Biotech Associations, and outreach projects to raise the profile

of European biotech among policymakers and the broader public.

HIGHLIGHTS

4th annual Biotech Week breaks new records

Recognising and promoting European biotech SMEs

Celebrating EuropaBio’s 20th anniversary

ICBA Global Life Sciences Ministerial-Industry Meeting

europabio.org/cross-sector

CROSS-SECTOR BIOTECH / 98 \

ANNUAL REPORT 2016-2017

The 2016 European Biotech Week, organised between 26

September and 2 October, broke new records building on

the success of 2015.

Not only did it feature in the first ever Global Biotech Week,

but it also set a new record with 16 European countries involved, including 3 newcomers:

Austria, Norway and Sweden. 135 activities and events organised across Europe involved

thousands of Europeans and ranged from open door days, symposiums, round table

discussions and competitions, to hands-on experiments and theatre shows.

4TH ANNUAL EUROPEAN BIOTECH WEEK BREAKS NEW RECORDS KEY FIGURES FOR THE WEEK INCLUDE:

11 media partners

58 media pick-ups across 11 countries

Informative events magazine

Amazing biotech history timeline

Twitter followers

#BiotechWeek tweets

visits of@biotechweek

including 38% growth over 1 week

135 events took place in 16 countr es

ON SOCIAL MEDIA

media outlets2

18 companies(including 4 EuropaBio members)

4 nationaloffices & councils

42 universities, schools & education centres

32 laboratories and research institutes

36 biotech, life sciences or business organisations(incl. 9 EuropaBio member national associations)

5museums

ALL WERE AMONG THE ORGANISERS GETTING INVOLVED IN THE WEEK

#

@

>1.600

>800

2.700



With the ‘Most Innovative European Biotech SME Awards’, now in their 7th year,

EuropaBio recognises exceptional small and medium-sized companies in Europe that

have developed novel ways of addressing our societal, technical, and environmental

problems through the application of biotechnology.

RECOGNISING AND PROMOTINGEUROPEAN BIOTECH SMES

The 2016 winners were:

The awards ceremony was the highlight of a top-level European Biotech SME Forum

attended by 12 CEOs and many other industry leaders. One of the Forum’s key

outcomes was the launch of the Call to Action for Biotech SMEs in Europe.

In addition to celebrating these exceptional SMEs, the 2016 awards were ground-

breaking in other ways too:

Agricultural biotech

category

Industrial biotech

category

Healthcare biotech

category

Plant Response Biotech,

a Spanish company

developing novel natural

products to confer

resistance and enhance

plant responses to biotic

and abiotic stress.

OxyMem, an Irish

company aiming to

revolutionise biological

aeration for industrial and

municipal wastewater

plants. The runners-up

in the industrial biotech

category were Biosyntia

and MetGen.

Cellectis, a French

biopharmaceutical

company developing

adoptive immunotherapies

for cancer. The runners-up

in the healthcare biotech

category were Oryzon

Genomics and TiGenix. 41 applications from12 countries

Plant Response Biotechwas the first ever agricultural

biotech SME prize winner.

www.biotechsmeawards.eubecame the initiative’s online

home and application hub.



We also celebrated our anniversary in other ways:

We marked the anniversary with a unique Charity Gala Dinner entitled ‘Back to the

Biotech Future’. Attended by 150 guests from industry, member companies and

associations, EU Institutions, academia, as well as former staff members, the event both

looked back at the evolution of the European biotech industry over the past twenty

years and looked forward to what the future holds. Thanks to their generosity, over

20.000€ was raised through a silent auction for an EMBO fund covering short-term

fellowships for talented researchers and their studies on systems biology and genomic

and computational science.

CELEBRATING EUROPABIO’S20TH ANNIVERSARY

In 2016, the International Council of Biotech Associations, of which EuropaBio is an

active and founding member, organised the inaugural Global Life Sciences Ministerial-

Industry Meeting entitled “How to Boost

Socio-Economic Benefits of Biotech Innovation

– Domestic Policy and Global Competition”. It

was attended by the Belgian Health Minister

Maggie De Block, the European Medicines

Agency’s Executive Director Guido Rasi, and

many other high-level representatives from

governments and biotech industries worldwide.

ICBA GLOBAL LIFE SCIENCESMINISTERIAL-INDUSTRY MEETING

We developed a special anniversary logo.

We created a Calendar of Biotech Benefits for members, stakeholders

and friends of EuropaBio.

We showcased our members in our weekly newsletter.

We retraced the history, achievements and challenges of

EuropaBio in a short video documentary.

HEALTHCAREBIOTECH

Improving patients’ access to innovative therapies is at the core of our

healthcare biotechnology membership and EuropaBio’s activities over the

past year.

In the coming year we will continue to:

• Call for enhanced patient access to healthcare biotechnology

innovations.

• Raise awareness of the value healthcare biotechnology brings to

patients, economies and societies.

• Maintain and build relationships with all relevant stakeholders to

encourage innovative policy solutions aimed at meeting patients’ needs

and addressing today’s and tomorrow’s challenges.

HIGHLIGHTS

‘Reward for Innovation’ Dinner Debate at the European Parliament

15/11/2016

European Medicines Agency – EuropaBio Information Day

22/11/2016

Buying Innovative in the Healthcare Biotech Market in Europe

Fostering the discussion on biosimilars labelling

How does Healthcare Biotech Benefit Europe?

europabio.org/healthcare-biotech

HEALTHCARE BIOTECH / 1716 \


The EuropaBio event ‘Reward for Innovation’ successfully showcased the various

viewpoints from the European Parliament, the European Commission, the Permanent

Representation of the Netherlands to the EU and the biotech industry on the challenges

and opportunities surrounding increased access to innovative healthcare products for

patients. In particular, it was highlighted that patients are at the centre of this debate

especially in areas of unmet medical needs such as rare diseases. There was a clear overall

wish from the audience and speakers to maintain the momentum of the debate with

EuropaBio’s help.

‘REWARD FOR INNOVATION’ DINNER DEBATE ATTHE EUROPEAN PARLIAMENT 15/11/2016

EUROPEAN MEDICINES AGENCY – EUROPABIO INFORMATION DAY 22/11/2016

The fourth EMA-EuropaBio Information Day took place in London.

Stakeholders discussed three main topics:

The full report of the Information Day

is available on the EMA website.

International Cooperation

with Medicines Agencies

Innovation and

Development Support

Evidence Generation During

Medicinal Life-Cycle

1 2 3

HEALTHCARE BIOTECH / 1918 \


Stakeholders agree that there is room for improving the labelling of biosimilars in

the EU. These were the overall conclusions of a workshop bringing together patients,

pharmacists and physicians that EuropaBio organised with the Association of

European Biopharmaceutical Enterprises in early 2016. A high-level summary of the

discussions was published in the GaBI Journal in early 2017. EuropaBio believes that

minor changes to biosimilar labelling in Europe will increase transparency and help to

facilitate physicians and patients’ understanding and acceptance of biosimilars.

In March 2017, EuropaBio released an

animated video showcasing the value of

healthcare biotechnology by creating and

delivering innovative treatments and

preventive interventions for the benefit

of patients and healthcare systems across

Europe. The achievements outlined in

this video reinforce the European biotech

industry’s commitment to continue

delivering innovative therapies that

improve patients’ lives, and to work with policymakers to

ensure the sustainability of Europe’s healthcare systems

while fostering biotech innovation. The video can be

found on the EuropaBio website.

FOSTERING THE DISCUSSION ON BIOSIMILARS LABELLING

HOW DOES HEALTHCARE BIOTECHBENEFIT EUROPE?

The adoption of the new European legislative package for public procurement in

February 2014 established a more efficient and flexible framework for the public

procurement of goods, works and services across the Union. This EuropaBio paper,

published in February 2017, proposes key steps to consider when purchasing biological

medicines, looking at each stage of the procurement process. It describes how the sound

use of public procurement can drive demand for and provision of innovative biological

medicines. Ultimately, it aims to identify how institutions and purchasing authorities can

facilitate competitive market demand for healthcare innovation in Europe.

‘BUYING INNOVATIVE’ IN THE HEALTHCAREBIOTECH MARKET IN EUROPE

AGRICULTURALBIOTECH

Genetically modified (GM) crops have been widely grown and consumed

for 20 years. EuropaBio has been working hard to communicate their

benefits and remove unnecessary barriers to GMOs, including GM grain

and soybean imports into the EU, and to promote EU farmers’ freedom of

choice. Improved regulatory certainty and better implementation of the

EU’s existing GMO authorization process are urgently needed to avoid

disruptions in the trade of much needed protein-rich animal feed.

HIGHLIGHTS

Unshackling Innovation

For a workable and predictable GMO authorisation system

Politics should not continue to trump science

Communicating about GMOs in Europe

europabio.org/agricultural-biotech

AGRICULTURAL BIOTECH / 2322 \


Supporting the EU’s own best science is critical for growth, innovation, and

investment. As various technologies for plant breeding and beyond are facing

political barriers in Europe, we joined forces with public researchers (PRRI) to

co-host the event “Unshackling Innovation: Will Europe block or enable GM crops?”

(27 September 2016, European Parliament) as part of European Biotech Week.

The event featured distinguished speakers such as Nobel laureate Sir Richard

Roberts and World Food Prize laureate Marc Van Montagu.

Together with partners in the Agri-Food Chain Coalition we continued to promote

innovation and consistency with some of the EU’s overarching policies.

UNSHACKLING INNOVATION

2016 marked the 20th anniversary of GM crop cultivation globally.

Despite an impeccable record of safe use and the many proven

societal benefits around the world, the process for granting market

authorisations to GMOs for import and cultivation in the EU remains

very politicised, very lengthy and highly unpredictable. In recognition

of the need to continuously raise broader awareness of these

problems in Europe, EuropaBio has been working together with

other stakeholders to help communicate to decision makers the

need to address inefficiencies in the EU’s risk assessment and risk

management procedures.

FOR A WORKABLE AND PREDICTABLE GMO AUTHORISATION SYSTEM

This year, EuropaBio has been leading the way as a partner in a multi-association

coalition, which has been calling on EFSA to deliver a well-structured and science-

based risk assessment process for GMOs within reasonable timeframes. Likewise, on

the risk management side, we united the voice of all interested parties and call for a

well-functioning and timely authorisation procedure for safety-assessed products, as

required by EU law.

Presentations, videos and pictures

from the ‘Unshackling Innovation’

event, which was relayed on Twitter,

can be found on the PRRI website

and on Flickr.

AGRICULTURAL BIOTECH / 2524 \


EuropaBio is concerned about post-truth politics in the area of GMOs and continues to

encourage Member States and the European Parliament to support the EU approval of

safe products, in line with the scientific evidence. We have also criticised recent policy

choices of the European Commission, which would make the EU’s access to agricultural

biotechnology even more difficult. In view of a new Commission proposal from February

2017 revising the decision-making rules for granting product authorisations, we warned,

together with 17 partner associations, that the EU must not pursue reforms at the

expense of innovation and the single market’s integrity.

POLITICS SHOULD NOT CONTINUE TO TRUMP SCIENCE

Communicating about GM crops and policies in the EU is not easy, but the Green G-Nome

can help. Our new and comprehensive pocket guide was published in April 2017. Covering

many facets of GMOs in Europe, the new guide is an essential communications tool that

we are promoting widely on social media. It complements and includes links to our series

of factsheets about the GMO approval process, risk assessment timelines, the benefits of

GM trade, voting behavior, and the danger of import bans. We think it is time for Europe

to face the facts on GMOs in the EU.

COMMUNICATING ABOUT GMOS IN EUROPE

EuropaBio continues to raise awareness and appreciation of the role of

Industrial Biotech as an enabler of a circular, bioeconomy for Europe which

is adding value, boosting competitiveness and fostering jobs, sustainable

economic growth and investment.

Active in numerous high level fora, the Association continues to foster

collaboration with other stakeholders, develop messaging and provide

intelligence on the role of white biotech in addressing some of Europe’s

most critical challenges. These include the provision of food, feed, fuel,

chemicals and other essential everyday materials for a growing, global

population through the development of renewable products and processes

which use resources more efficiently.

Contributing to numerous high-level events, expert groups and panels,

which seek to overcome barriers to the commercialisation of EU bio-based

solutions, EuropaBio has also focused on several core activities over the

last 12 months with the aim of ensuring greater deployment of industrial

biotechnology and access to its accompanying benefits.

HIGHLIGHTS

European Bioeconomy Alliance

New study shows jobs and growth generated by Industrial Biotech on the rise

EFIB 2016

18/10/2016 - 20/10/2016

DG GROW Bio-Based Products Expert group workshop

02/12/2016

Moving towards a Circular Bioeconomy in Europe

INDUSTRIALBIOTECH

europabio.org/industrial-biotech

INDUSTRIAL BIOTECH / 2928 \


EuropaBio is playing a very active role in the work of the European Bioeconomy Alliance.

Comprised of 12 leading European organisations, the Alliance advocates for the creation

of a more favourable and supportive environment for the development of a world

leading, sustainable and competitive bioeconomy in Europe, while raising awareness of

the bio-based sectors and their benefits.

EUROPEAN BIOECONOMY ALLIANCE

MEPs Lambert van Nistelrooij and Franc Bogovič hosted the report

launch event in the European Parliament and EuropaBio continues to

actively share the findings of the study in external events, with policy

makers and other stakeholders.

Industrial Biotech contributes over €30 billion to the EU economy and around

500.000 jobs, with figures expected to grow to between 900.000-1.5 million jobs

with an accompanying economic contribution of up to almost €100 billion by 2030.

Those were the key findings of a new EuropaBio report, prepared to highlight the

increasing potential of Industrial Biotech to contribute towards Europe’s jobs, growth

and competitiveness agenda, which was commissioned and prepared by EuropaBio,

published in September 2016.

NEW STUDY SHOWS JOBS AND GROWTH GENERATED BY INDUSTRIAL BIOTECH ON THE RISE

bioeconomyalliance.eu

INDUSTRIAL BIOTECH / 3130 \


>500attendeesexhibition space

The Expert Group held a workshop on the sustainability of bio-based products,

coordinated by EuropaBio. With participation of officials from the Commission, Member

States, European Parliament and other stakeholders, the workshop aimed to enable an

open and informed discussion on several themes around the sustainability of bio-based

products. The workshop was a great success in attendance with approximately

75 participants, with much interest and active discussions.

Rather than developing the circular economy and the bioeconomy in parallel, greater

integration will contribute with benefits for the environment, economy and society.

EuropaBio is actively advocating for a greater emphasis on the interlinkages between the

two, inter alia through its work in the context of the European Bioeconomy Alliance, the

EU Bioeconomy Stakeholders Panel and ongoing collaboration with other organisations.

DG GROW BIO-BASED PRODUCTS EXPERT GROUP WORKSHOP 02/12/2016

MOVING TOWARDS A CIRCULAR BIOECONOMYIN EUROPE

EuropaBio’s Congress on Industrial Biotech and the Bioeconomy, EFIB, has grown from 80

people in 2008 to over 500 people in 2016. It provides a meeting place for the entire

bio-based value chain, enabled by industrial biotech, and draws together influencers and

thought leaders from business, policy and beyond. Preparations for EFIB 2017 in the SQUARE

Brussels from 9-11 October are well underway – we look forward to seeing you there.

EFIB 2016 18/10/2016 - 20/10/2016

and a SOLDOUT

35from over

countr es

LAST YEAR’S CONGRESS TOOK PLACE IN GLASGOW, SCOTLAND AND FEATURED:

Several wellattended

networkingevents.

Approximately

100 HIGH-LEVELSPEAKERS

including Dame Anne Glover & Paul Gilding, representatives from the European Commission, IKEA, P&G, Unilever, PSA Group, Tetra Pak, Ecover, Ellen MacArthur Foundation, Celtic Renewables and many more.

First ever EFIB ‘pitchfest‘ won by MetGen awarded

by a panel of Venture Capitalists for most

promising new product or process.

Numerous session tracks on forging the

link between the circular economy and the

bioeconomy, feedstocks of the future, innovation, international and regional

strategy development, brand owners and climate

change mitigation.

3F-Bio revealed as winners of coveted John Sime award for innovation.

OUR TEAM / 3332 \


OUR TEAMJohn Brennan

Secretary General Since June 2017

Nathalie MollSecretary General Until March 2017

Joanna Dupont-InglisDirector, Industrial

Biotechnology

Cosmin PopaManager, Communications

& National Associations

Mélanie MoxhetCommunications & Office

CoordinatorUntil November 2016

Davide MarchiManager, Healthcare

BiotechnologySince December 2016

Delphine CarronRegulatory Affairs Manager, Agricultural Biotechnology

Until March 2017

Clément RobijnsCommunications & Office

CoordinatorSince November 2016

Riccardo MezzasalmaManager, Healthcare

BiotechnologyUntil September 2016

Violeta GeorgievaLegal and Regulatory Manager,

Agricultural Biotechnology

Petra KostolaniovaRegulatory Affairs Officer,Agricultural Biotechnology

Since March 2017

Ronald JagerDirector, Healthcare

BiotechnologySince August 2016

Pedro Narro SanchezPublic Affairs Manager,

Agricultural Biotechnology

Christopher GallaschCommunications Manager,Agricultural Biotechnology

Alexander GibbsManager, Healthcare

Biotechnology

Christine DevauxIT Manager &

PA to the Secretary General

Beat SpäthDirector, Agricultural

Biotechnology

Catherine De FeyterDirector, Finance, HR & Office Administration

Agnes BorgManager, Industrial

Biotechnology

OUR MEMBERS / 3534 \


OUR MEMBERSOur membership includes a wide range of corporate members and industry associations

involved in biotechnology throughout Europe. EuropaBio has 50 corporate and

27 associate members and BIO Regions and 16 national biotechnology associations –

representing some 1800 small and medium-sized enterprises across Europe.

AbbVie

Ajinomoto Eurolysine

Alexion

ARD

Amgen

Areta International

BASF

Bayer

Bio Amber

Biogen

Biomarin

Carbios

Clariant

Corbion

CSL Behring

Clementia Pharmaceuticals

Dow AgroSciences

DuPont

Eli Lilly

Erytech

Evonik Industries

Horizon Pharma

Intrexon Actobiotics

Keygene

KWS SAAT SE

Knowledge Transfer Network Ltd

Limagrain

Merck KGaA

Monsanto

Merck & Co

NatureWorks

Novamont

Novartis

Novo Nordisk

Novozymes

Nestec

Orphan Europe

Pfizer

PTCBIO

Royal DSM

Roquette

Shire

SOBI

Solvay

Syngenta

Sanofi Genzyme

Transgene

UniQure

Vertex Pharmaceuticals

2-BBB Medicines

Biosyntia

Bluebird Bio

Cambridge Biomedical

Consultants

Celtic Renewables

Cellectis

Deerfield

Dr. Regenold

Expert Services & Advice in

Healthcare BVBA

EORTC

Iden

Intellia Therapeutics

Kedrion Biopharma

MolMed

MetGen

Nanobiotix

Oryzon Genomics

OxyMem

Perseus

Plant Response Biotech

Redx Pharma

SFL Pharma

Svanvid

TNO

TiGenix

Voisin Consulting Life Sciences

Italy | Assobiotec Federchimica

Spain | Asebio

Belgium | Bio.be

Germany | Bio Deutschland

Ireland | BioPharmaChem

UK | Bioindustry Association

Denmark | Dansk Biotek

Germany | DIB

Finland | Finnish Bioindustries

France | France Biotech

The Netherlands | HollandBIO

Norway | Norwegian Bioindustry Association

Portugal | P-BIO

Sweden | SwedenBio

Switzerland | Swiss Biotech Association

Switzerland | Scienceindustries

CORPORATE MEMBERS

ASSOCIATE MEMBERS AND BIO REGIONS

NATIONAL ASSOCIATIONS

EuropaBio aisbl Avenue de l’Armée 6, 1040 Brussels, Belgium

t. +32 2 735 03 13 | f. +32 2 735 49 60

www.europabio.org

Documents

ANNUAL REPORT 2016-2017 · 8 \ CROSS-SECTOR BIOTECH / 9 ANNUAL REPORT 2016-2017 The 2016 European Biotech Week, organised between 26 September and 2 October, broke new records building